13 results for author:"Gallimore J.R." in Literature citations
Results Customize
› Repeat search in UniProtKB (1)
| Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use. Pepys M.B., Gallimore J.R., Lloyd J., Li Z., Graham D., Taylor G.W., Ellmerich S., Mangione P.P., Tennent G.A., Hutchinson W.L. et al. J. Immunol. Methods 384:92-102(2012) · Mapped (4) |
| Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Kolstoe S.E., Ridha B.H., Bellotti V., Wang N., Robinson C.V., Crutch S.J., Keir G., Kukkastenvehmas R., Gallimore J.R., Hutchinson W.L. et al. Proc. Natl. Acad. Sci. U.S.A. 106:7619-7623(2009) · Mapped (1) |
| Serum amyloid A, C-reactive protein, and retinal microvascular changes in hypertensive diabetic and nondiabetic individuals: an Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) substudy. Stettler C., Witt N., Tapp R.J., Thom S., Allemann S., Tillin T., Stanton A., O'Brien E., Poulter N., Gallimore J.R. et al. Diabetes Care 32:1098-1100(2009) · Mapped (3) |
| Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice. Tennent G.A., Hutchinson W.L., Kahan M.C., Hirschfield G.M., Gallimore J.R., Lewin J., Sabin C.A., Dhillon A.P., Pepys M.B. Atherosclerosis 196:248-255(2008) · Mapped (3) |
| Normal circulating serum amyloid P component concentration in systemic sclerosis. Tennent G.A., Dziadzio M., Triantafillidou E., Davies P., Gallimore J.R., Denton C.P., Pepys M.B. Arthritis Rheum. 56:2013-2017(2007) · Mapped (1) |
| Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Leslie K.S., Lachmann H.J., Bruning E., McGrath J.A., Bybee A., Gallimore J.R., Roberts P.F., Woo P., Grattan C.E., Hawkins P.N. Arch Dermatol 142:1591-1597(2006) · Mapped (4) |
| Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Lachmann H.J., Sengul B., Yavuzsen T.U., Booth D.R., Booth S.E., Bybee A., Gallimore J.R., Soyturk M., Akar S., Tunca M. et al. Rheumatology (Oxford) 45:746-750(2006) |
| Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Pepys M.B., Hawkins P.N., Kahan M.C., Tennent G.A., Gallimore J.R., Graham D., Sabin C.A., Zychlinsky A., de Diego J. Circ. Res. 97:e97-103(2005) · Mapped (17) |
| Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Hirschfield G.M., Gallimore J.R., Kahan M.C., Hutchinson W.L., Sabin C.A., Benson G.M., Dhillon A.P., Tennent G.A., Pepys M.B. Proc. Natl. Acad. Sci. U.S.A. 102:8309-8314(2005) · Mapped (16) |
| Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Clapp B.R., Hirschfield G.M., Storry C., Gallimore J.R., Stidwill R.P., Singer M., Deanfield J.E., MacAllister R.J., Pepys M.B., Vallance P. et al. Circulation 111:1530-1536(2005) · Mapped (3) |
| Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Pepys M.B., Herbert J., Hutchinson W.L., Tennent G.A., Lachmann H.J., Gallimore J.R., Lovat L.B., Bartfai T., Alanine A., Hertel C. et al. Nature 417:254-259(2002) · Mapped (5) |
| Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Noursadeghi M., Bickerstaff M.C., Gallimore J.R., Herbert J., Cohen J., Pepys M.B. Proc. Natl. Acad. Sci. U.S.A. 97:14584-14589(2000) · Mapped (2) |
| Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Pepys M.B., Rademacher T.W., Amatayakul-Chantler S., Williams P., Noble G.E., Hutchinson W.L., Hawkins P.N., Nelson S.R., Gallimore J.R., Herbert J. et al. Proc. Natl. Acad. Sci. U.S.A. 91:5602-5606(1994) · UniProtKB (1) |